Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

29.27 +0.11 (+0.38%)
Official Closing Price Updated: 7:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,987,720
Open 29.16
Bid (Size) 29.18 (8)
Ask (Size) 29.24 (1)
Prev. Close 29.16
Today's Range 28.99 - 29.32
52wk Range 25.20 - 34.41
Shares Outstanding 5,606,688,356
Dividend Yield 5.60%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
From Pfizer Inc.
Via Business Wire
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs

Performance

YTD
-1.55%
-1.55%
1 Month
+1.35%
+1.35%
3 Month
+6.32%
+6.32%
6 Month
+4.76%
+4.76%
1 Year
-14.29%
-14.29%

More News

Read More
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
Via Investor's Business Daily
Got $5,000? 3 Dirt Cheap Stocks to Buy Right Now
Via The Motley Fool
Should You Buy Novavax Stock After This Regulatory Win?
Via The Motley Fool
A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now
Via The Motley Fool
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
Via MarketBeat
Exposures Product Safety
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Via Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
Via Benzinga
Is Hims & Hers Health the Next Teladoc?
Via The Motley Fool
Exposures COVID-19
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
From Pfizer Inc.
Via Business Wire
2 Beaten-Down Stocks That Could Be Great Buys on the Dip
Via The Motley Fool
3 High-Yield Stocks to Buy Hand Over Fist in September
Via The Motley Fool
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Why Is Moderna Stock Trading Higher On Monday?
Via Benzinga
Exposures COVID-19
Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
Via Benzinga
3 No-Brainer Dividend Stocks With Yields Above 5% You Can Buy Now and Hold at Least a Decade
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in September
Via The Motley Fool
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
Via Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
Via Benzinga
Exposures Product Safety
A Few Years From Now, You'll Wish You Had Bought This Undervalued Stock
Via The Motley Fool
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Via Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Walgreens Boots Alliance Fell Another 22% in August
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.